Participants take 500 mg of PolyResveratrol (100 mg curcumin phytosome, 100 mg quercetin phytosome, 100 mg green tea phytosome, 100 mg trans-resveratrol, 100 mg trans-pterostilbene; Thorne Research) twice daily for one week. Two blood Draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.

Participants take 500 mg of Curcumin phytosome twice daily for one week. Two blood draws are taken on both the first and last days of the week. One blood draw is done fasted just before consumption of one supplement dose, and one blood draw is done after consumption of one supplement dose.

Inflammation

Atherosclerosis

Cardiovascular Disease

Participants will take 1 mg of a polyresveratrol phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the polyresveratrol phytosome supplement on inflammation will be examined along with the short-term effect (1 week).

PolyResveratrol Supplementation

Participants will take 1 mg of a curcumin phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the curcumin phytosome supplement on inflammation will be examined along with the short-term effect (1 week).

Curcumin Supplementation

Clinical Exercise Research Center

Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL

VCAM-1 and ICAM-1 expression in whole plasma will be measured at baseline, and one hour after a single dose of each supplement using flow cytometry. Differences in one-hour changes in inflammation between each supplement will be compared.

VCAM-1 and ICAM-1 expression in whole plasma will be measured at baseline, and after one week of supplementation for each supplement using flow cytometry. Differences in one-week changes in inflammation between each supplement will be compared.

VCAM-1 and ICAM-1 expression in HDL plasma will be measured at baseline, and one hour after a single dose of each supplement using flow cytometry. Differences in one-hour changes in inflammation between each supplement will be compared.

VCAM-1 and ICAM-1 expression in HDL plasma will be measured at baseline, and after one week of supplementation for each supplement using flow cytometry. Differences in one-week changes in inflammation between each supplement will be compared.

HDL cholesterol efflux capacity will be measured at baseline, one hour after a single dose, and after a week of supplementation in non-apolipoprotein B containing plasma.

University of South Carolina

Patients receive curcumin PO BID for 180 days in the absence of unacceptable toxicity.

Patients receive placebo PO BID for 180 days in the absence of unacceptable toxicity.

Chronic Atrophic Gastritis

Curcumin

Laboratory Biomarker Analysis

Placebo Administration

Quality-of-Life Assessment

Hospital Regional de Occidente

University of Puerto Rico

Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia

Randomized, Double-Blind, Placebo-Controlled Trial of Meriva® (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis

Will be measured by Luminex assay. If the data are not normally distributed, the Wilcoxon Rank-Sum test will be used. The 95% confidence intervals will also be provided.

Will be graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4. The maximum grade for each type of adverse event will be recorded for each participant and frequency tables will be reviewed to determine the overall patterns. The number and severity of adverse events (overall and by intervention group) will be tabulated and summarized.

Will compare changes in histology gastric score for curcumin versus placebo.

Will be quantified with Luminex assay. Changes in the concentrations (or categories) will be explored within and between the intervention arms. Fisher's exact tests, Wilcoxon rank sum tests, and two-sample t-tests will be used to assess differences between groups. McNemar's tests, Wilcoxon signed rank tests, and paired sample t-tests will be used to assess differences within each arm. Graphical methods (i.e. boxplots, scatter plots, etc.) will also be used to describe the data.

Will be assessed by immunohistochemistry. Fisher's exact tests, Wilcoxon rank sum tests, and two-sample t-tests will be used to assess differences between groups. McNemar's tests, Wilcoxon signed rank tests, and paired sample t-tests will be used to assess differences within each arm. Graphical methods (i.e. boxplots, scatter plots, etc.) will also be used to describe the data.

Will be examined in relation to the outcomes above to further characterize the at-risk population and generate hypotheses for future studies.

National Cancer Institute (NCI)

Placebo
Placebo: daily placebo for 6 weeks

Placebo

Total

Sex: Female, Male

Ethnicity (NIH/OMB)

Race (NIH/OMB)

The primary outcome to be measured will be the change in NF-kB DNA binding (measured in peripheral blood mononuclear cells as ng/well) after six weeks of treatment with daily placebo or Meriva. NF-kB DNA binding and has been associated with fatigue in breast cancer patients.

PBMC NF-kB DNA Binding Measured in ng/Well

The secondary outcome to be measured will be the change in plasma TNF-alpha after six weeks of treatment with daily placebo or Meriva. Plasma TNF-alpha is a downstream mediator of NF-kB DNA binding and has been associated with fatigue in breast cancer patients.

Plasma TNF-alpha

The secondary outcome to be measured will be the change in plasma sTNFR2 (in pg/ml) after six weeks of treatment with daily placebo or Meriva. Plasma sTNFR2 is a downstream mediator of NF-kB DNA binding and has been associated with fatigue in breast cancer patients.

Plasma sTNFR2 Measured in pg/ml

The secondary outcome to be measured will be the change in plasma IL-1ra (in pg/ml) after six weeks of treatment with daily placebo or Meriva. Plasma IL-1ra is a downstream mediator of NF-kB DNA binding and has been associated with fatigue in breast cancer patients.

Plasma IL-1ra Measured in pg/ml

The primary outcome to be measured will be the change in plasma IL-6 after six weeks of treatment with daily placebo or Meriva.

Plasma IL-6 Measured in pg/ml

The primary outcome to be measured will be the change in plasma CRP after six weeks of treatment with daily placebo or Meriva.

Plasma C-reactive Protein (CRP) Measured in mg/L

The secondary outcome to be measured will be the change in fatigue (as measured by the Multidimensional Fatigue Inventory [MFI] total score) after six weeks of treatment with daily placebo or Meriva. The MFI is a 20-item scale designed to evaluate fatigue. Respondents use a scale ranging from 1 to 5 for each item to indicate how statements regarding fatigue represent their experiences. The range of scores is from a minimum of 20 and a maximum of 100. Higher total scores correspond with more acute levels of fatigue.

curcuminoid/necrosis

Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL

Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia

Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy

科学支持的最完整的草药数据库